Global Health Ltd
MEDANTA NSE
Global Health Ltd
Healthcare ServicesNSE: MEDANTA BSE: 543654 Hospitals
Key Fundamentals
SmallcapHospitalsHealthcare ServicesMarket Cap
₹39,169 Cr
Volatility
Moderate
P/E Ratio
70.35
EBITDA
₹918 Cr
Return on Equity
14.21%
Debt to Equity
0.3
Book Value
₹147.34
EPS
₹17.97
52W High
₹1,475.8
52W Low
₹956
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Global Health Ltd insights
39 extracted metrics + investor summaries across FY16–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
1- Company has delivered good profit growth of 80.7% CAGR over last 5 years
Weaknesses
1- Stock is trading at 9.88 times its book value
Growth Rate
Revenue Growth
16.94% ↗
Net Income Growth
21.29% ↗
Cash Flow Change
1.91% ↗
ROE
-13.62% ↘
ROCE
-9.67% ↘
EBITDA Margin (Avg.)
-19.68% ↘
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 3d agoAI opinion · based on fundamentals
Risk medium
Global Health Ltd (Medanta) is a mid-large cap hospital chain with a market cap of ~₹38,289 crore trading at a PE of 69.9x and 9.74x book value. The company delivered FY26 consolidated revenue of ~₹4,410 crore (up ~20% YoY) and PAT of ~₹554 crore (up ~15% YoY), with an aggressive expansion plan to add ~3,200 beds over the next 3-4 years. The stock reflects premium growth expectations against a backdrop of high valuations relative to current earnings.
Bull Case 8
- Strong 5-year profit CAGR of ~81%, indicating significant operating leverage as the hospital network matures
- FY26 consolidated revenue grew ~20% YoY to ₹4,410 crore, demonstrating sustained top-line momentum
- EBITDA margin (ex-Noida) at ~25.7% in FY26, reflecting disciplined cost management at mature hospitals
- Aggressive bed addition pipeline of ~500 beds in next 12 months and ~2,700 beds via 5 greenfield projects over 3-4 years, providing long-term revenue visibility
- International patient revenue grew 22-23% YoY, diversifying the revenue base beyond domestic payors
- 3-year stock CAGR of 28% reflects market recognition of the growth trajectory
- Debt-to-equity ratio of ~0.30x is manageable for a hospital business in expansion mode, with total debt of ~₹1,190 crore against equity of ~₹3,980 crore
- Inpatient volumes grew ~14% YoY and occupied bed days rose ~13% YoY in recent quarters, showing organic demand growth
Bear Case 8
- PE of 69.9x is significantly above the healthcare sector average, leaving limited room for execution missteps
- Price-to-book of 9.74x means investors are paying a steep premium over net asset value
- TTM profit growth has decelerated to ~0% despite 21% revenue growth, suggesting margin pressures or one-time costs
- Noida greenfield hospital is still loss-making and dragging consolidated EBITDA margins down to ~23-24% from ex-Noida levels of ~25.7%
- Dividend yield of just 0.03% offers virtually no income return to shareholders
- Greenfield expansion of ~2,700 beds over 3-4 years will require significant capex, potentially increasing leverage during the gestation period
- ROE of ~15-16% over 3 years is moderate for the premium valuation commanded, implying the stock is priced for significant ROE expansion
- International patient revenue faced sequential decline due to geopolitical disruptions (West Asia conflict), highlighting external vulnerability
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 1d ago Headwinds 1
- Q1FY27 profit declines Jul 30
Global Health reported Q1FY27 standalone PAT of ₹1,373.07 million, marking a dip from prior period. Profit decline signals potential margin pressure in the quarter ended June 2026.
Positives 3
- ₹970 crore Guwahati expansion approved Jul 30
Board approved ₹970 crore expansion of Guwahati hospital to 650 beds, signaling aggressive capacity addition in Northeast India. New beds should drive future revenue growth once operational.
- New CDO appointment Jul 30
Pradeep Kumar Singh appointed as Chief Digital Officer, indicating strategic investment in digital capabilities and operational efficiency.
- 20,000 ESOPs granted to employee Jul 30
Nomination and Remuneration Committee granted 20,000 stock options under GHL LTIP 2024 Plan at exercise price of ₹1,147 each. Helps with talent retention and aligns employee interests with shareholders.
Neutral 1
- Q1 FY27 earnings call scheduled Jul 25
Conference call scheduled for July 31, 2026 hosted by JM Financial to present Q1 FY27 results. Company's top leadership to share insights on quarter ended June 30, 2026.
TL;DR: Global Health is investing heavily in capacity expansion with the ₹970 crore Guwahati hospital project (650 beds) and strengthening leadership, but Q1FY27 saw a profit dip that warrants monitoring. The ESOP grants and CDO appointment reflect long-term strategic thinking. The key question going forward is whether margin pressures are temporary or structural, and whether the expansion pipeline can drive earnings recovery in coming quarters.
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 780 | 844 | 836 | 809 | 861 | 957 | 943 | 931 | 1,031 | 1,099 | 1,121 | 1,159 | 1,304 |
| Expenses | 595 | 631 | 620 | 629 | 675 | 728 | 706 | 707 | 784 | 868 | 904 | 915 | 1,017 |
| Operating Profit | 184 | 213 | 216 | 179 | 186 | 228 | 238 | 225 | 247 | 231 | 217 | 244 | 287 |
| OPM % | 24% | 25% | 26% | 22% | 22% | 24% | 25% | 24% | 24% | 21% | 19% | 21% | 22% |
| Other Income | 15 | 21 | 18 | 27 | 22 | 18 | 16 | -27 | 20 | 36 | -15 | 37 | 22 |
| Interest | 18 | 20 | 18 | 18 | 18 | 16 | 16 | 15 | 14 | 17 | 22 | 27 | 27 |
| Depreciation | 40 | 43 | 44 | 45 | 47 | 49 | 48 | 49 | 45 | 50 | 61 | 67 | 69 |
| PBT | 141 | 171 | 172 | 143 | 144 | 181 | 189 | 133 | 208 | 200 | 120 | 187 | 213 |
| Tax % | 28% | 27% | 28% | 11% | 26% | 28% | 24% | 24% | 24% | 21% | 21% | 24% | 26% |
| Net Profit | 102 | 125 | 124 | 127 | 106 | 131 | 143 | 101 | 159 | 158 | 95 | 142 | 157 |
| EPS in Rs | 3.8 | 4.66 | 4.61 | 4.74 | 3.96 | 4.87 | 5.32 | 3.78 | 5.92 | 5.89 | 3.54 | 5.36 | 5.9 |
Profit & Loss
| Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,382 | 1,343 | 1,456 | 1,500 | 1,447 | 2,167 | 2,710 | 3,275 | 3,692 | 4,410 | 4,683 |
| Expenses | 1,081 | 1,218 | 1,283 | 1,309 | 1,250 | 1,709 | 2,073 | 2,466 | 2,806 | 3,491 | 3,705 |
| Operating Profit | 301 | 125 | 172 | 192 | 197 | 458 | 637 | 809 | 886 | 919 | 979 |
| OPM % | 22% | 9% | 12% | 13% | 14% | 21% | 24% | 25% | 24% | 21% | 21% |
| Other Income | 45 | 49 | 50 | 44 | 31 | 39 | 49 | 75 | 29 | 98 | 80 |
| Interest | 14 | 28 | 38 | 57 | 73 | 86 | 86 | 84 | 74 | 79 | 92 |
| Depreciation | 70 | 86 | 102 | 115 | 123 | 130 | 150 | 173 | 194 | 223 | 246 |
| PBT | 262 | 60 | 83 | 64 | 32 | 281 | 449 | 627 | 647 | 715 | 720 |
| Tax % | 35% | 45% | 38% | 43% | 11% | 30% | 27% | 24% | 26% | 23% | — |
| Net Profit | 170 | 33 | 51 | 36 | 29 | 196 | 326 | 478 | 481 | 554 | 552 |
| EPS in Rs | 35.1 | 6.78 | 10.44 | 7.36 | 5.81 | 7.75 | 12.16 | 17.81 | 17.92 | 20.7 | 20.69 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 48 | 48 | 49 | 49 | 50 | 51 | 54 | 54 | 54 | 54 |
| Reserves | 976 | 1,136 | 1,246 | 1,300 | 1,333 | 1,565 | 2,375 | 2,852 | 3,333 | 3,908 |
| Borrowings | 165 | 456 | 787 | 929 | 931 | 1,109 | 1,122 | 802 | 718 | 1,190 |
| Other Liabilities | 295 | 343 | 347 | 388 | 380 | 421 | 547 | 572 | 662 | 753 |
| Total Liabilities | 1,485 | 1,984 | 2,430 | 2,666 | 2,694 | 3,146 | 4,097 | 4,280 | 4,766 | 5,905 |
| Fixed Assets | 914 | 1,094 | 1,194 | 1,703 | 1,616 | 1,776 | 2,050 | 2,236 | 2,514 | 3,795 |
| CWIP | 12 | 317 | 666 | 382 | 464 | 439 | 327 | 388 | 533 | 132 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 |
| Other Assets | 559 | 573 | 570 | 581 | 615 | 930 | 1,720 | 1,656 | 1,716 | 1,975 |
| Total Assets | 1,485 | 1,984 | 2,430 | 2,666 | 2,694 | 3,146 | 4,097 | 4,280 | 4,766 | 5,905 |
Cash Flow
| Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 228 | 63 | 166 | 175 | 242 | 311 | 645 | 612 | 624 | 714 |
| Investing | -241 | -69 | -249 | -87 | -239 | -421 | -342 | -441 | -721 | -1,089 |
| Financing | -7 | 9 | 97 | -1 | -81 | 160 | 346 | -514 | -97 | 272 |
| Net Cash Flow | -20 | 3 | 14 | 87 | -78 | 50 | 648 | -343 | -194 | -103 |
| Free Cash Flow | 71 | -81 | -133 | -13 | 100 | 38 | 409 | 335 | 110 | -263 |
| CFO/OP | 108 | 93 | 135 | 121 | 131 | 89 | 118 | 98 | 89 | 91 |
Ratios
| Mar 2016 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 20 | 41 | 41 | 36 | 34 | 30 | 26 | 24 | 29 | 34 |
| Inventory Days | 28 | 26 | 26 | 43 | 42 | 36 | 35 | 32 | 28 | 29 |
| Days Payable | 92 | 124 | 142 | 147 | 138 | 90 | 114 | 90 | 81 | 89 |
| Cash Conversion Cycle | -45 | -56 | -75 | -67 | -62 | -24 | -52 | -34 | -24 | -26 |
| Working Capital Days | -23 | -33 | -18 | -31 | -48 | -20 | -37 | -32 | -21 | -7 |
| ROCE % | — | — | 6% | 6% | 5% | 15% | 17% | 20% | 20% | 17% |
Documents
1
Announcement under Regulation 30 (LODR)-Meeting Updates
15h - Global Health granted 10,000 ESOPs to one employee under GHL LTIP 2024 on May 11, 2026. 15h - Global Health granted 10,000 ESOPs to one employee under GHL LTIP 2024 on May 11, 2026.
2
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
8h - Medanta schedules Q4 FY2026 earnings conference call on May 15, 2026 at 2:00 PM IST, hosted by ICICI Securities. 8h - Medanta schedules Q4 FY2026 earnings conference call on May 15, 2026 at 2:00 PM IST, hosted by ICICI Securities.
3
Board Meeting Intimation for Approval Of Audited Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2026 And Recommendation Of Final Dividend.
6 May - Board meets May 14, 2026 to approve FY26 audited results and consider final dividend. 6 May - Board meets May 14, 2026 to approve FY26 audited results and consider final dividend.
4
Announcement under Regulation 30 (LODR)-Acquisition
27 Apr - Approved BTA to acquire 79-bed cancer hospital in Indore for Rs 30 crore, adding capacity. 27 Apr - Approved BTA to acquire 79-bed cancer hospital in Indore for Rs 30 crore, adding capacity.
5
Announcement under Regulation 30 (LODR)-Meeting Updates
27 Apr - Board approved BTA for 79-bed Indore cancer hospital acquisition for Rs 30 crore; completion by September 30, 2026. 27 Apr - Board approved BTA for 79-bed Indore cancer hospital acquisition for Rs 30 crore; completion by September 30, 2026.
Frequently Asked Questions about Global Health Ltd
What does Global Health Ltd do?
Global Health Limited is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India. The company has key specialties in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transp...
Where is Global Health Ltd (MEDANTA) listed?
Global Health Ltd is listed on the Indian stock exchanges. It is listed on NSE: MEDANTA and BSE: 543654. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Global Health Ltd belong to?
Global Health Ltd operates in the Healthcare Services sector within the Hospitals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Global Health Ltd?
Global Health Ltd has a market capitalisation of approximately ₹39168.66 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Global Health Ltd?
The Price-to-Earnings (PE) ratio of Global Health Ltd is 70.35. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Global Health Ltd?
Over the past 52 weeks, Global Health Ltd has traded between a low of ₹956 and a high of ₹1,475.8. This range helps investors understand the stock's price volatility and recent trading levels.
Does Global Health Ltd pay dividends?
Yes, Global Health Ltd has a dividend yield of 0.03%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Global Health Ltd?
Global Health Ltd has a Return on Equity (ROE) of 14.21%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Global Health Ltd on Tapetide?
On Tapetide, you can view Global Health Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Global Health Limited is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India. The company has key specialties in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology.[1]